Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAvMed AmBisome Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Amphotericin B liposome (AmBisome) prior authorization

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines AvMed medical prior authorization and step-edit criteria for amphotericin B liposome (AmBisome) for outpatient medical administration, including required documentation, eligible diagnoses, prescriber requirements, and reauthorization conditions for members.

    Policy Summary
    PayerAvMed
    PolicyAmphotericin B liposome (AmBisome) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrescriber must complete and sign the medical prior authorization request and submit supporting documentation including chart notes, lab results, diagnostics, and pharmacy paid claims.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsInitial authorization duration
    3 monthsReauthorization duration
    J0289HCPCS code listed for AmBisome

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredSpecialist prescriber

    Coverage Criteria for Amphotericin B Liposome (AmBisome)

    Initial Authorization

    Covered when ALL of the following are met

    Prescriber and diagnosis requirements: Prescribed by or in consultation with an infectious disease and/or transplant specialist AND member has one of the listed diagnoses (cryptococcal meningitis in patients with HIV; febrile neutropenic patients with presumed fungal infection; systemic infections caused by Aspergillus, Candida, and/or Cryptococcus; visceral leishmaniasis)

    Must be verified by documentation.

    Justification for liposomal formulation: Member must meet ONE of the following: refractory to conventional amphotericin B deoxycholate therapy OR has renal impairment or unacceptable toxicity that precludes use of the deoxycholate formulation OR has tried and failed ONE of the specified first-line therapies when applicable (flucytosine, voriconazole, posaconazole, caspofungin IV)

    Prior therapies and refractoriness/intolerance must be verified by chart notes or pharmacy paid claims; some listed agents require prior authorization themselves (e.g., flucytosine, posaconazole).

    Reauthorization

    Covered when ALL of the following are met

    Monitoring and benefit: Provider attests renal function is being monitored and no preclusions due to toxicity have been observed AND submits documentation confirming the member's condition has improved or stabilized, or that continued therapy is medically necessary and the benefits outweigh the risks (e.g., HIV)

    Reauthorization period is 3 months.

    Use of manufacturer or office samples to initiate amphotericin B liposome therapy does not meet step edit/preauthorization criteria and therefore cannot be used in lieu of prior authorization requirements.

    Amphotericin B liposome (AmBisome) is not covered when the member does not meet the specified eligible diagnoses (cryptococcal meningitis in patients with HIV; febrile neutropenia with presumed fungal infection; systemic infections caused by Aspergillus, Candida, and/or Cryptococcus; or visceral leishmaniasis) or when there is no documentation of refractoriness to conventional amphotericin B deoxycholate, no renal impairment/unacceptable toxicity precluding deoxycholate use, and no evidence of failure of listed alternative therapies (e.g., flucytosine, voriconazole, posaconazole, caspofungin) as verified by chart notes or pharmacy paid claims.

    Coding

    Covered HCPCS CodesHCPCSCovered
    J0289Injection, amphotericin B liposomal, 1 mg

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Amphotericin B liposome (J0289). The prescribing physician must complete and sign the medical prior authorization form (preprinted stamps are not valid) and fax to 1-877-535-1391. If the information provided is not complete, correct, or legible, authorization can be delayed or denied.

    • Code: J0289 (Amphotericin B liposome)
    • Form must be signed by prescribing physician (no preprinted stamps)
    • Fax completed form to 1-877-535-1391
    Documentation Required

    Clinical Prerequisites

    All clinical criteria must be met for approval. Member must have one of the listed diagnoses and must be refractory to conventional amphotericin B deoxycholate therapy, have renal impairment or unacceptable toxicity that precludes deoxycholate, or have tried and failed an applicable first-line therapy (verified by chart notes or pharmacy paid claims).

    Definitions

    Refractory to deoxycholate — definition
    DefinitionFailure to respond to conventional amphotericin B deoxycholate therapy as verified by chart notes or pharmacy paid claims.
    Verification sourcesChart notes documenting lack of clinical response to amphotericin B deoxycholate.
    Alternate verificationPharmacy paid claims showing prior dispensing of amphotericin B deoxycholate without clinical improvement.
    Context of useUsed to justify step-up to amphotericin B liposome when member meets eligible diagnoses (e.g., cryptococcal meningitis, systemic Aspergillus/Candida/Cryptococcus infections, febrile neutropenia, visceral leishmaniasis).
    Reauthorization documentation
    Provider attestation requirementProvider attests renal function is being monitored and no preclusions due to toxicity have been observed.

    Background

    Amphotericin B liposome (AmBisome) is used for serious systemic fungal infections and for visceral leishmaniasis and is generally reserved when conventional amphotericin B deoxycholate is not tolerated or is contraindicated. The policy requires that a specialist (infectious disease and/or transplant) prescribe or consult, and that prior therapies, refractoriness to deoxycholate, or renal impairment/toxicity be documented via chart notes or pharmacy paid claims to justify use of the liposomal formulation.

    Policy Summary
    PayerAvMed
    PolicyAmphotericin B liposome (AmBisome) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrescriber must complete and sign the medical prior authorization request and submit supporting documentation including chart notes, lab results, diagnostics, and pharmacy paid claims.
    SourceLink
    On This Page
    Coverage Criteria for Amphotericin B Liposome (AmBisome)CodingProvider Actions and Documentation RequirementsDefinitionsBackground
    • Member must have ONE qualifying diagnosis (e.g., cryptococcal meningitis with HIV; febrile neutropenia with presumed fungal infection; systemic Aspergillus/Candida/Cryptococcus infections; visceral leishmaniasis).
    • Member must meet ONE of the following: refractory to amphotericin B deoxycholate; renal impairment or unacceptable toxicity to deoxycholate; or tried and failed an applicable first-line therapy (e.g., flucytosine, voriconazole, posaconazole, caspofungin IV) verified by chart notes or pharmacy paid claims.
    Documentation Required

    Documentation to Provide

    Provide all supporting documentation with the request. Authorization may be delayed or denied if documentation is incomplete.

    • Chart notes supporting diagnosis and clinical course
    • Relevant lab results (including renal function) and date obtained
    • Diagnostic test results
    • Pharmacy paid claims or medication history verifying prior therapies or failures
    • Weight (if applicable) and date weight obtained
    • Provider attestation that renal function is being monitored for reauthorization requests
    Denial Risk

    Incomplete Information Risks

    Incomplete, incorrect, or illegible information can delay or result in denial of the authorization. Missing required documentation — such as lab results, diagnostics, chart notes, or evidence of prior therapies/paid claims — may lead to denial.

    • Ensure all fields on the prior authorization form are complete and legible
    • Missing lab results, diagnostics, chart notes, or paid-claim evidence may result in denial
    • For Medicare members, ensure compliance with applicable NCDs/LCDs
    Documentation to submitDocumentation confirming the member's condition has improved or stabilized, or that continued therapy is medically necessary and benefits outweigh risks (e.g., in HIV).
    Reauthorization periodReauthorization may be granted for 3 months when requirements are met.
    Evidence acceptableClinical progress notes and relevant laboratory results demonstrating renal monitoring and clinical course.